Gilead exercises license for Assembly Biosciences herpes programs
Source: SeekingAlpha
2025-12-22 11:42:00 ET
More on Gilead Sciences
- Gilead Sciences, Inc. (GILD) Presents at Evercore 8th Annual Healthcare Conference Transcript
- Gilead Sciences, Inc. (GILD) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
- Gilead Sciences: About To Break Out
- Bristol Myers, Merck, Amgen among latest to announce U.S. drug pricing deal
- More pharmas expected to sign drug pricing deals with Trump on Friday - report
Read the full article on Seeking Alpha
For further details see:
Gilead exercises license for Assembly Biosciences herpes programs
Assembly Biosciences Inc.
NASDAQ: ASMB
ASMB Trading
-2.16% G/L:
$28.97 Last:
20,466 Volume:
$29.05 Open:
ASMB Latest News
December 22, 2025 08:00:00 am
Gilead Sciences Exercises Option to License Assembly Biosciences' Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes
December 08, 2025 04:05:00 pm
Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Studies of Long-Acting Helicase-Primase Inhibitor Candidates ABI-1179 and ABI-5366 Showing Reductions in Viral Shedding Rate and Virologically Confirmed Genital Lesion Rate in Re
November 10, 2025 04:05:00 pm
Assembly Biosciences Reports Third Quarter 2025 Financial Results and Recent Updates
ASMB Stock Data
$431,017,065
8,905,050
58.72%
12
N/A
Biotechnology & Life Sciences
Healthcare
US
South San Francisco
